Moderna stock kpis
Want to see MRNA full AI Analyst Report?
Operating Expense Breakdown
Moderna reported operating expenses of $867.00M in Q2 2026, up 5.5% from Q1 2026 and down 6.8% year over year. The highest value was $1.88B in Q4 2023.
Details core costs like R&D, marketing, and admin, offering insight into how efficiently Moderna runs and where it’s prioritizing investment, crucial for understanding its focus on innovation and market expansion.
R&D and SG&A have been pared back sharply from their pandemic-era peaks as Moderna shifts from volume-driven spending to a leaner operating base—this reflects Phase III wind‑downs and explicit cost discipline. Management confirms lower adjusted cash costs and SG&A targets while keeping R&D weighted to H2, so investment is being deferred rather than cut entirely. That boosts adjusted profitability but raises execution risk for late‑stage programs and global commercialization; the large litigation settlement inflates GAAP losses but is distinct from the OpEx trend.
MRNA Operating Expense Breakdown
| Period | Research and Development | Selling, General, and Administrative | Total |
|---|---|---|---|
| Q2 2026Jun 30, 2026 | $651.00M | $216.00M | $867.00M |
| Q1 2026Mar 31, 2026 | $649.00M | $173.00M | $822.00M |
| Q4 2025Dec 31, 2025 | $775.00M | $308.00M | $1.08B |
| Q3 2025Sep 30, 2025 | $801.00M | $268.00M | $1.07B |
| Q2 2025Jun 30, 2025 | $700.00M | $230.00M | $930.00M |
| Q1 2025Mar 31, 2025 | $856.00M | $212.00M | $1.07B |
| Q4 2024Dec 31, 2024 | $1.12B | $351.00M | $1.47B |
| Q3 2024Sep 30, 2024 | $1.14B | $281.00M | $1.42B |
| Q2 2024Jun 30, 2024 | $1.22B | $268.00M | $1.49B |
| Q1 2024Mar 31, 2024 | $1.06B | $274.00M | $1.34B |
| Q4 2023Dec 31, 2023 | $1.41B | $470.00M | $1.88B |
| Q3 2023Sep 30, 2023 | $1.16B | $442.00M | $1.60B |
| Q2 2023Jun 30, 2023 | $1.15B | $332.00M | $1.48B |
| Q1 2023Mar 31, 2023 | $1.13B | $305.00M | $1.44B |
| Q4 2022Dec 31, 2022 | $1.21B | $375.00M | $1.59B |
| Q3 2022Sep 30, 2022 | $820.00M | $278.00M | $1.10B |
| Q2 2022Jun 30, 2022 | $710.00M | $211.00M | $921.00M |
| Q1 2022Mar 31, 2022 | $554.00M | $268.00M | $822.00M |
| Q4 2021Dec 31, 2021 | $648.00M | $201.00M | $849.00M |
| Q3 2021Sep 30, 2021 | $521.00M | $168.00M | $689.00M |
| Q2 2021Jun 30, 2021 | $421.00M | $121.00M | $542.00M |
| Q1 2021Mar 31, 2021 | $401.00M | $77.00M | $478.00M |
| Q4 2020Dec 31, 2020 | $758.85M | $78.73M | $837.58M |
| Q3 2020Sep 30, 2020 | $344.49M | $48.54M | $393.03M |
| Q2 2020Jun 30, 2020 | $152.00M | $37.00M | $189.00M |
| Q1 2020Mar 31, 2020 | $115.00M | $24.00M | $139.00M |

